Andere talen AVEO Pharmaceuticals, Inc. Börse Stuttgart

Aandelen

VPA

US0535881090

Vertraagde tijd Börse Stuttgart Andere beurzen 16:33:53 05-10-2021			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,28 ^EUR	-0,19%		-10,02%	+20,93%

13/06	LG Chem Company en AVEO Oncology kondigen aan dat LG Chem's eerste gepatenteerde antikankermengsel aan een Fase 1 klinische studie begint, de dosering is gestart in de VS	CI
25/03	AVEO Pharmaceuticals, Inc. Kondigt Executive Changes aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S	13/06
AVEO Pharmaceuticals, Inc. Announces Executive Changes	25/03
Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist	06/02
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	16/01
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma	27-06-23
South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1%	20-01-23
AVEO Completes Acquisition by LG Chem	20-01-23
LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals	20-01-23
AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	19-01-23
LG Chem Completes Acquisition of AVEO Oncology	19-01-23
AVEO Pharmaceuticals, Inc. Announces Management Changes	19-01-23
AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer	19-01-23
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index	19-01-23
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index	19-01-23
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index	19-01-23
LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders.	19-01-23
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger	18-01-23
AVEO Pharmaceuticals : Merger Agreement - Form 8-K	18-01-23
AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	18-01-23
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger	06-01-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AVEO Pharmaceuticals, Inc. Börse Stuttgart

Aandelen

VPA

US0535881090

Andere talen

Filters